MicroPort Orthopedics Makes Major Overseas Moves with Strategic Leadership Appointments and Global Expansion

Source: Instrument Family, unauthorized reproduction is prohibited, and reprinting is allowed 24 hours later.

Recently,器械之家 learned that MicroPort Orthopedics USA announced the recruitment of two strategic executives.Namely, Brian Collins and Shawn Gabriel, where Brian Collins will serve as the Global Vice President of Marketing, and Shawn Gabriel will serve as the Vice President of Sales for North America;Two senior executives have extensive experience in the sales and marketing of medical devices.

It is reported that MicroPort Orthopedics originated from Shanghai MicroPort Medical (Group) Co., Ltd., which was established in 1998. Starting from 2009, it has undergone more than ten years of independent research and development, as well as efficient integration of global resources and markets.Achieved global operation of orthopedic business, becoming one of the largest orthopedic companies in China.In recent years, as MicroPort Medical Group has continuously strengthened its overseas presence, MicroPort Orthopedics has also achieved frequent breakthroughs in international markets.

01

One of the largest orthopedic device enterprises in China

MicroPort was founded in 1998 as an innovative high-end medical device group. Its business covers twelve major clusters, including cardiovascular and structural heart disease, electrophysiology and heart rhythm management systems, bone and soft tissue repair technology, aortic and peripheral vascular diseases, cerebrovascular and neuromodulation sciences, surgical critical care and robotics, endocrine management and assisted reproduction, urology, gynecology, gastrointestinal, respiratory diseases, ear, nose, mouth, eye, body, and other aesthetic treatments, in-vitro diagnostics and imaging inside and outside the body, solid tumor treatment technology within the body, insomnia, depression, and rehabilitation medicine.

In 2009, the company established Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. to begin laying out its orthopedic business in China. In September 2011, it acquired 100% of the equity of Suzhou Best, which owns a product line series for trauma and spine. In 2012, MicroPort Orthopedics Medical Technology (Suzhou) Co., Ltd. was founded in the Suzhou Industrial Park.In 2014, acquired the relevant assets of OrthoRecon ("Joint Reconstruction Business") from U.S.-based Wright Medical for $290 million.

It is understood that Wright is a U.S. publicly traded company focusing on the design, manufacture, and sale of orthopedic implants and biomaterials. Headquartered in Arlington, Tennessee, with over 60 years of history and more than 1,500 employees, it is an orthopedic company with a global sales network. The annual sales revenue of the OrthoRecon division acquired by MicroPort is approximately $270 million, accounting for about 60% of Wright's total sales.After the completion of the acquisition, MicroPort Orthopedics became one of the top six global companies in hip and knee reconstruction businesses at that time.

After more than a decade of independent research and development, along with the efficient integration of global resources and markets, MicroPort Orthopedics has achieved global operations for its core business and has become one of the largest orthopedic companies in China.Joint products have benefited nearly 1.4 million patients worldwide; the company has more than 1,000 employees globally; its products are marketed and serviced in over 70 countries and regions, with offices set up in multiple major cities around the world.

Currently, the two headquarters of MicroPort® Orthopedics are located in Arlington, Tennessee, USA, and Suzhou Industrial Park, China.Memphis, USA serves as the R&D, manufacturing, and global logistics distribution center. It has a group of professional management and technical talents along with advanced production and testing equipment. In the past three years, it has developed more than ten new orthopedic joint products, helping patients achieve faster full-function recovery.

The China headquarters of MicroPort® Orthopedics, located in Suzhou, is an orthopedic innovation industrial park integrating functions such as research and development, manufacturing, logistics, and academia.In July 2019, the Renshou Hall Training Center in the park was officially launched, providing a hardware and software platform for MicroPort® Orthopedics to exchange and cooperate with universities, research institutions, and medical experts.

02

Newly Appointed Global Vice President of Marketing

Former executive of Zimmer Biomet and Stryker

After completing the acquisition of Wright's OrthoRecon division, MicroPort established its global headquarters for MicroPort® Orthopedics in Arlington, Tennessee, USA. In recent years, as the company has continuously strengthened its overseas presence, revenue from MicroPort Orthopedics' overseas markets has accounted for a significant portion of its annual revenue.

In 2021, MicroPort's orthopedic business overseas revenue reached 193 million USD, increasing by 11.8% year-on-year, accounting for nearly 90%. The domestic market was affected by the centralized procurement of artificial joints, resulting in the orthopedic business revenue in China reaching 22 million USD in 2021, decreasing by 31.7% year-on-year. During the reporting period, the overall business loss narrowed significantly by 57.3%.

The announcement of Brian Collins and Shawn Gabriel joining the company is also one of its important initiatives in the commercialization of overseas markets.

It is reported that Brian Collins has over 12 years of experience in the medical device industry, bringing leading strategic and execution experience to the MicroPort orthopedics team.During his recent tenure as Global Vice President of Marketing and Medical Education at ZimVie, he led the successful spin-off of Zimmer Biomet. Prior to joining ZimVie, Brian Collins worked at Stryker,Deep Synthesis and Zimmer Biomet MET, among other companies, have held various positions in sales, marketing, and other fields.

Shawn Gabriel has over 20 years of experience in the medical device industry, leading sales teams and exceeding performance targets. Shawn has worked for Johnson & Johnson, Smith & Nephew, Medtronic, etc.During his tenure in various positions at these companies, he consistently excelled in revenue growth, sales team efficiency, and the sale of medical device solutions. He has extensive experience leading sales teams within independent distribution networks as well as in direct sales. In his previous roles, Shawn consistently fostered a culture aligned with corporate values and focused on delivering performance as a cohesive unit. As Vice President of Sales for MicroPort North America, Shawn will leverage his experience and leadership to align and exceed sales targets.

Rob Cripe, Chief Commercial Officer of MicroPort Orthopedics, said, "Brian and Shawn's expertise will provide our commercial leadership team with the necessary tools to continue our strategic growth in the United States and beyond." "Their joining our team is another way for MicroPort Medical Group to prioritize becoming a leader in the medical device industry."

03

Global Layout with M&A

As an innovative high-end medical device group, MicroPort currently has over 400 products on the market, which have entered more than 10,000 hospitals worldwide. Globally, on average, a MicroPort® product is used every six seconds to save lives, improve patients' quality of life, or help bring new life into the world.

Starting from 2012, MicroPort began implementing the "10+5 Joint Fleet" group operation model and accelerated its development towards diversification, corporatization, and globalization. By 2014, after completing the acquisition of Wright Medical's large joint reconstruction business and establishing MicroPort® Orthopedics' global headquarters in Arlington, Tennessee, USA, MicroPort officially embarked on its global layout.In the same year, MicroPort established a joint venture with Italy's SORIN to form MicroPort™ Cardiac Rhythm Management, developing cardiac rhythm management products in China, and acquired the drug-eluting stent-related assets of Cordis, a subsidiary of U.S.-based Johnson & Johnson.

On August 11, 2016, MicroPort Scientific Corporation (hereinafter referred to as "MicroPort®") announced the official establishment of its Indian subsidiary, which is registered as MicroPort Scientific India Private Limited.As a new member of MicroPort® Medical Group, the goal of the Indian subsidiary is to serve the Indian market by providing cost-effective medical solutions that can save and reshape lives or improve the quality of life for Indian patients.

In 2017, MicroPort, in partnership with Yunfeng Capital, acquired Liva Nova's Sorin heart rhythm management business for $1.9 billion, making it the world's fifth-largest supplier of cardiac rhythm management devices.Enter the cardiac rhythm management business. In the same year, it also acquired the Brazilian distributor's business and launched MicroPort's localized management in Brazil.

In 2018, the company established the global headquarters of MicroPort® Cardiac Rhythm Management in Paris, France, to expand its cardiac rhythm management business;In 2020, MicroPort strategically invested in the Indian medical device company Purple Medical and established a joint venture.

Last October, the company once again acquired German Hemovent for nearly 1 billion yuan.The company's main product, the MOBYBOX System, is the world's first ECMO system that integrates the blood pump and membrane lung into a single unit.

On October 29, 2021, MicroPort issued a voluntary announcement stating that it would acquire 38.33% of Argus Medical Technology Co., Ltd. for a transaction price of 372 million yuan. After the capital increase is completed, MicroPort will own 51% of Argus and gain control of the company.In addition, in September 2021, MicroPort also acquired 45% of CoreRay Pharma. This move is considered as MicroPort's intervention into the upstream raw material sector, accelerating the overseas expansion of drug-eluting stents.

MicroPort Coronary Rapamycin-Eluting Stent System

Through a series of acquisitions and strategic investments, MicroPort has initiated its layout in multiple fields such as neurointervention, surgical instruments, surgical robotics, and orthopedics. The company has also established major production (R&D) bases in Shanghai, Suzhou, Jiaxing, Shenzhen in China, Memphis in the United States, the suburbs of Paris in France, the suburbs of Milan in Italy, and the Dominican Republic, forming a global R&D, production, marketing, and service network.